Clinuvel Pharmaceuticals (CUV) H1 2025 earnings summary

Executive summary

• Achieved record underlying profit and double-digit revenue growth for H1 FY2025, driven by increased patient treatment, SCENESSE® expansion, and controlled expenses.

• Treated more patients and distributed more SCENESSE® implants than any previous first half, with expansion of North American Specialty Centers to 93 and further growth planned.

• Declared and paid seventh consecutive dividend following FY2024 results.

• Board renewal with three new Non-Executive Directors and clinical team restructuring, prioritizing strategic programs in vitiligo, ACTH, and porphyrias.

• Business model leverages direct distribution, long-term prescriber relationships, and rare disease infrastructure.

Financial highlights

• Total revenue for H1 FY2025 was $43.3 million, up 21.1% year-over-year, with commercial sales and reimbursements for SCENESSE® increasing 10.5%.

• Profit before tax rose 48.1% to $21.9 million; profit after tax increased 28.7% to $14.1 million.

• Basic earnings per share increased 27.4% to $0.28.

• Cash and term deposits reached $198.2 million, up 7.8% from June 2024.

• Interest income rose 26% to $4.62 million, benefiting from higher rates and term deposit strategies.

Outlook and guidance

• Ongoing revenue growth expected, underpinned by increased patient numbers, high retention, adolescent treatment, higher dose frequency in Europe, and expansion into new jurisdictions.

• Expansion to 120 North American Specialty Centers targeted, with key 2025 events including regulatory decisions in Europe and Canada, and new product launches.

• Completion of CUV105 vitiligo study recruitment targeted for June 2025; CUV107 study to commence.

• Launch of next-generation CYACÊLLE product and further clinical/regulatory milestones expected in 2025.

• Expenses anticipated to rise as investment continues in late-stage Vitiligo and other clinical programs.